FDA Conditional Acceptance of Lyrfigtu Brand Name
Analysis based on 7 articles · First reported Sep 22, 2026 · Last updated Sep 22, 2026
The FDA conditional brand-name acceptance is a modest positive milestone for Elevar Therapeutics and its parent HLB Co., Ltd., keeping the lirafugratinib commercialization path on track ahead of the September 25, 2026 PDUFA date. Market reaction is likely muted until the actual approval decision, though a positive outcome could lift HLB shares on the KOSDAQ while a rejection would weigh on the stock.
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., announced on September 22, 2026 that the U.S. United States — Food and Drug Administration granted conditional acceptance of LYRFIGTU as the brand name for lirafugratinib. The drug is currently under FDA Priority Review as a treatment for patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusion or other rearrangement. Final acceptance of the brand name will be established upon FDA approval of lirafugratinib. In January 2026, the FDA accepted Elevar's new drug application for lirafugratinib and subsequently granted Priority Review, assigning a Prescription Drug User Fee Act target action date of September 25, 2026. In the Phase 1/2 ReFocus trial, lirafugratinib demonstrated a confirmed objective response rate of 46% and a median duration of response of 11.8 months in patients with the proposed indication. Elevar holds an exclusive license to lirafugratinib from Relay Therapeutics, Inc. for worldwide commercialization. Elevar CEO Dong-Gun Kim called the conditional acceptance another important milestone and said the company is preparing for a potential launch. HLB Co., Ltd. trades on the KOSDAQ, where its stock closed at KRW 31,050.00, down 2.82 percent.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard